Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy Cancer Treatment Reviews November 2022;110
Date
11/01/2022
DOI
10.1016/j.ctrv.2022.102461Scopus ID
2-s2.0-85137057610 (requires institutional sign-in at Scopus site)
61 CitationsAuthor List
Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, Kurzrock R
Author
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of Wisconsin